KESIMPTA 20 mg/.4mL (Ofatumumab INJECTION, SOLUTION) 20 mg/.4mL

KESIMPTA 20 mg/.4mL is a subcutaneous injection solution containing ofatumumab. This medication is used to manage specific autoimmune conditions. Learn more about its uses and effects.

Strength

20 mg/.4mL

Pack Size

1 SYRINGE, GLASS in 1 CARTON (0078-1007-98) / .4 mL in 1 SYRINGE, GLASS

Manufacturer / TM Owner

Novartis Pharmaceuticals Corporation

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

KESIMPTA 20 mg/.4mL is primarily used for the treatment of relapsing forms of multiple sclerosis. This medication works by targeting specific cells in the immune system to reduce inflammation and slow disease progression. People often ask, 'What is KESIMPTA used for?' It is designed to help manage symptoms and reduce the frequency of relapses in multiple sclerosis.

Side Effects

Common effects of KESIMPTA 20 mg/.4mL may include injection site reactions, such as redness, swelling, or itching. Some individuals might experience fatigue, fever, or muscle pain. These effects vary and are not exhaustive; always consult a healthcare provider for personalized advice.

Precautions & Warnings

KESIMPTA 20 mg/.4mL should be handled with care. It is important to store the medication as directed and use it under medical supervision. Avoid self-administration without proper guidance. Always follow the prescribed guidelines for handling and disposal.

Avoid Interactions

KESIMPTA 20 mg/.4mL may interact with other medications, including those that affect the immune system. It is crucial to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain supplements might also affect how this medication works.

Frequently Asked Questions

KESIMPTA is used to treat relapsing forms of multiple sclerosis by targeting specific immune cells.

KESIMPTA is administered as a subcutaneous injection, typically under medical supervision.

Common side effects may include injection site reactions, fatigue, fever, and muscle pain.

KESIMPTA may interact with other medications, so it's important to consult a healthcare provider before combining treatments.

KESIMPTA should be stored according to the instructions provided, typically in a refrigerator.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.